Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,575.19
(
-0.75%
)
US TECH 100
23,566.71
(
-0.96%
)
Dow Jones
45,788.30
(
-0.95%
)
Brent Oil
107.50
(
0.86%
)
Bitcoin
69,417.50
(
-2.56%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jbog

Send PM Follow Ignore
Followers 64
Posts 11870
Boards Moderated 0
Alias Born 07/16/2006

jbog

Re: DewDiligence post# 159059

Sunday, 03/31/2013 11:29:25 AM

Sunday, March 31, 2013 11:29:25 AM

Post# of 257259
It isn't Gilenya's price that prevents usage rather the problem lies in its safety and testing profiles.

You are correct that historically patients did not change MS drugs often. Sadly, that was yesterday. It all involves the safety profile.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now